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Acetyl-CoA carboxylase (ACC), the first committed enzyme in fatty
acid (FA) synthesis, is regulated by phosphorylation/dephosphory-
lation, transcription, andanunusualmechanismof proteinpolymer-
ization. Polymerization of ACC increases enzymatic activity and is
induced in vitro by supraphysiological concentrations of citrate
(>5 mM). Here, we show that MIG12, a 22 kDa cytosolic protein
of previously unknown function, binds to ACC and lowers the
threshold for citrate activation into the physiological range
(<1 mM). In vitro, recombinant MIG12 induced polymerization of
ACC (as determined by nondenaturing gels, FPLC, and electron
microscopy) and increased ACC activity by >50-fold in the presence
of 1 mM citrate. In vivo, overexpression of MIG12 in liver induced
ACCpolymerization, increased FA synthesis, andproduced triglycer-
ideaccumulationand fatty liver. Thus, inaddition to its regulationby
phosphorylation and transcription, ACC is regulated at a tertiary
level byMIG12, which facilitates ACC polymerization and enhances
enzymatic activity.
lipogenesis ∣ SREBPs ∣ steatosis
Fatty acids (FAs) are the essential components of phospholipidsand provide the most important energy depot for the body in
the form of triglycerides (TG). Newly synthesized FAs also serve
as signaling molecules and modulators of transcription factor
activity (1–3). Excess accumulation of FAs in tissues contributes
to the pathogenesis of many common diseases, including insulin
resistance, nonalcoholic fatty liver disease, diabetes, and cancer
(4, 5). Given the central role of FAs in these diseases, the enzymes
of FA biosynthesis are potential therapeutic targets.
The first committed step in FA biosynthesis is carried out by
acetyl-CoA carboxylase (ACC). ACC1 was isolated and charac-
terized byWakil et al. (6) and functions to carboxylate acetyl-CoA
to form malonyl-CoA. Subsequently, a second ACC isoform,
ACC2, was identified in mammals that is encoded by a separate
gene but carries out the same enzymatic reaction (7, 8).
ACCs are members of a larger family of carboxylases that
require biotin and ATP and use bicarbonate as a carbon donor.
The malonyl-CoA produced by ACC can be used by FA synthase
(FAS) for the sequential 2-carbon elongation reactions that
generate palmitic acid (C16:0) in the cytosol. While both
ACC1 and ACC2 produce malonyl-CoA, ACC1 is predominantly
cytosolic and generates malonyl-CoA that is used by FAS to
synthesize palmitic acid. ACC2 is associated with the mitochon-
drial membrane (9) and produces malonyl-CoA that serves to
allosterically inhibit carnitine palmitoyl transferase I, the protein
responsible for transport of long chain FAs into mitochondria for
β-oxidation (10).
Regulation of ACC1 and ACC2 occurs at multiple levels. ACC
activity is acutely regulated by phosphorylation/dephosphoryla-
tion. AMP-activated protein kinase phosphorylates ACC and
inhibits enzyme activity (11). In the fed state, excess glucose must
be converted to FAs for energy storage in the form of TGs.
Increased insulin signaling in the fed state results in the depho-
sphorylation of ACC, which increases ACC activity and stimu-
lates FA synthesis in liver (12).
The second level of regulation of ACC is transcriptional, which
is mediated by sterol regulatory element-binding protein-1c
(SREBP-1c), carbohydrate response element-binding protein
(ChREBP), and liver X receptors (LXRs) (13–15). Insulin stimu-
lates FA synthesis in liver through LXR, which transcriptionally
induces SREBP-1cmRNA(16). SREBP-1c activates the transcrip-
tion of ACC and all enzymes involved in FA biosynthesis (13).
ChREBP is activated by glucose and independently activates genes
encoding the FA biosynthetic enzymes (17).
The third level of regulationofACCactivity is throughallosteric
activation by high concentrations of citrate, which can induce the
polymerization of ACC and thereby increase enzymatic activity
(4). Citrate is produced in the mitochondria and is used as a
substrate by ATP citrate lyase (ACL), which converts citrate to
acetyl-CoA, the substrate of ACC. The overall contribution of
this third level of regulation has been questioned inasmuch as
the concentrations of citrate required to increase ACC activity
are much higher than that normally present in cells (18, 19).
To identify novel proteins involved in lipid metabolism, we car-
ried out microarray studies of mice that either overexpressed
SREBPs or that lacked SREBPs in the liver (20). There are three
SREBP family members, designated SREBP-1a, -1c, and -2. The
SREBP-1 isoforms predominantly regulate genes involved in FA
and TG synthesis while the SREBP-2 isoform activates genes in-
volved in cholesterol biosynthesis and cellular homeostasis (13).
One gene identified in our array screen was Mig12 (20), a gene
that encodes an ∼22 kDa protein that was subsequently reported
to cooperate with MID1 to bundle and stabilize microtubules
(21). MIG12 mRNA levels were increased in livers of SREBP
transgenic mice and significantly reduced in liver of mice that
lacked SREBPs (20). Although a function of MIG12 in lipid
metabolism was unknown, the regulation of MIG12 mRNA levels
by SREBPs suggested that one might exist. Here, we show that
MIG12 induces the polymerization of ACC1 and ACC2, which in
turn increases total ACC enzymatic activity. Citrate is not
required for MIG12-induced polymerization of ACC1. Polymer-
ization of ACC2 requires low concentrations of citrate. MIG12 is
incorporated into the ACC polymers. These studies identify
MIG12 as a SREBP-regulated tertiary regulator of ACC activity.
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Results
MIG12 is Expressed in All Tissues and Is a Cytosolic Protein. MIG12
mRNA is expressed in all tissues with the highest levels in liver,
heart, brain, and kidney (Fig. S1A), and white adipose tissue (22).
The hydrodropathy plot of MIG12 suggested that there were no
transmembrane domains (Fig. S1B). As a first step in interrogat-
ing the function of MIG12, the cellular localization of MIG12 in
liver was determined. Liver proteins were separated into nuclear,
cytosolic, and membrane fractions, and proteins in each fraction
were separated by SDS/PAGE. MIG12 was identified by immu-
noblot analysis using an antibody raised against recombinant
mouse MIG12 protein. As shown in Fig. S1C, MIG12 protein
was detected only in the cytosolic fraction of mouse liver.
MIG12 Expression Is Regulated in a Manner Similar to Other Proteins
Involved in Lipogenesis.FA synthesis is normally suppressed during
fasting and induced by refeeding carbohydrate-enriched diets
(23). Mice were fasted or refed a high carbohydrate diet following
a 12 h fast and hepatic MIG12 mRNA and protein levels were
measured. In the fasted state, MIG12 mRNA and protein levels
were reduced by∼80%, while the refed mice exhibited an increase
of 2.2-fold of both mRNA and protein relative to mice fed ad
libitum (Fig. S2). MIG12 appeared as a doublet on immunoblot
analysis of mouse liver cytosol with molecular weights of ∼22
and ∼24 kDa. This pattern of regulation is similar to that of
SREBP-1c (Fig. S2) and other enzymes involved in FA synth-
esis (23).
Overexpression of MIG12 in Mice Increases De Novo Hepatic FA Synth-
esis.To elucidate whether MIG12 had a direct function in FA me-
tabolism, an adenovirus that expressed MIG12 was injected into
C57BL/6 male mice. Mice infected with an adenovirus expressing
β-gal were used as controls. Five days after virus administration,
mice were injected with tritiated water and in vivo rates of hepatic
FA and cholesterol synthesis measured (Fig. 1A). Mice that over-
expressed MIG12 in liver had ∼2-fold higher rates of de novo FA
synthesis, which culminated in∼3-fold higher hepatic TG concen-
trations and the development of fatty livers (Fig. 1B). In vivo
cholesterol synthesis rates and liver concentrations were not
changed by MIG12 overexpression.
To investigate the mechanism by which MIG12 selectively
increased FA synthesis, the mRNA levels of the genes that
encode enzymes involved in the de novo synthesis of FAs in livers
of mice infected with the MIG12 adenovirus were quantified and
compared to mice injected with control virus. No significant
changes in mRNA levels of ACL, ACC1, ACC2, FAS, elongation
of long chain FAs (ELOVL) 6, or stearoyl-CoA desaturase-1 were
observed, and nuclear protein levels of the transcription factors
that activate the lipogenic genes, SREBP-1 and ChREBP, were
not increased by MIG12 overexpression (Fig. S3A and B). Simi-
larly, protein levels of ACL, ACC, and FAS were unchanged by
MIG12 overexpression in liver (Fig. S3C). Thus, the increase in
hepatic FA synthesis induced by MIG12 was independent of
transcriptional activation and the steady state protein levels of
lipogenic enzymes.
MIG12 Binds to ACC. Coimmunoprecipitation studies were carried
out to determine whether MIG12 interacted with proteins that
might influence FA synthesis. Mice were injected with an adeno-
virus expressing β-gal or FLAG-tagged MIG12, and livers were
harvested 2 d after injection. MIG12 was immunoprecipitated
using an anti-FLAG antibody and proteins that coimmunopreci-
pitated were separated by SDS/PAGE and visualized by silver
stain. Proteins that preferentially coimmunoprecipitated with
MIG12 were identified using the Procise® Protein Sequencing
System. One prominent protein that coimmunoprecipitated pre-
ferentially with MIG12 was identified as ACC (Fig. S4); the en-
zyme that carries out the first committed step in FA synthesis.
To determine whether MIG12 interacted with other FA biosyn-
thetic enzymes, mice were injected with an adenoviruses expres-
sing β-gal or FLAG-tagged MIG12 and killed after a 12 h fast or
after refeeding a high carbohydrate diet. MIG12 was immunopre-
cipitated using the anti-FLAG antibody, and the proteins were
Fig. 1. MIG12 overexpression in mice increases FA synthesis resulting in fatty
liver. Five mice were injected with adenoviruses (1011 particles∕mouse) that
expressed β-gal or MIG12. Each value represents the average S:E: of values
from 5 mice and P values were determined using Student’s t-test. (A) In vivo
rates of FA and cholesterol synthesis in livers of mice injected with β-gal or
MIG12 adenovirus. Five days after adenoviral injections, mice were injected
intraperitoneally with ½3HH2O (50 mCi) and 3H incorporation into newly
synthesized FAs and cholesterol were measured as described in Methods.
Similar results were obtained in 1 independent study. (B) Liver TG and
cholesterol concentrations were measured 5 days after adenoviral injections.
Similar results were obtained in three independent studies.
Fig. 2. ACC coimmunoprecipitates with MIG12. (A) Five male mice were
injected with an adenovirus expressing either β-gal or MIG12-FLAG. Two days
after injection, mice were fasted for 12 h (F) or refed a high carbohydrate diet
for 12 h following a 12 h fast (R). Livers were harvested andMIG12 was immu-
noprecipitated from liver lysates using an anti-FLAG monoclonal antibody.
Cell lysates and proteins in immunoprecipitation pellets were separated by
SDS/PAGE and immunoblot analysis was performed using polyclonal antibo-
dies that recognize mouse ACC1, FAS, and ACL as described in Methods.
(B) Five male mice were fed chow ad libitum (C), fasted for 12 h (F), or refed
ahigh carbohydratediet for 12hafter a12h fast (R). Liverswereharvestedand
endogenous MIG12 was immunoprecipitated from cell lysates using an anti-
mouse MIG12 polyclonal antisera or rabbit preimmune sera. Proteins in the
supernatant and immunoprecipitation pellets were separated by SDS/PAGE
and immunoblot analysis was performed using polyclonal antibodies that
recognize mouse ACC1 and MIG12. * cross-reacting band.
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subjected to SDS/PAGE and immunoblot analysis using antibo-
dies that recognize ACL, ACC, and FAS. As shown in Fig. 2A,
only ACC coimmunoprecipitated with MIG12, and the amount
of ACC precipitated was greater from livers of mice refed the
high carbohydrate diet, a state in which ACC protein is most
abundant.
To confirm that the interaction between MIG12 and ACC
occurred at physiological levels of MIG12 expression, a polyclo-
nal antibody raised against mouse MIG12 was used for immuno-
precipitation of endogenous MIG12 from livers of mice fed ad
libitum, fasted for 12 h, and refed a high carbohydrate diet
following a fast (Fig. 2B). In ad libitum and refed conditions,
ACC coimmunoprecipitated with MIG12; in the fasted state,
endogenous MIG12 was not detected in liver.
MIG12 Increases ACC Activity. Inasmuch as MIG12 directly bound
to ACC under physiological conditions, we next determined
whether MIG12 altered ACC activity using an in vitro assay
developed by Lane and coworkers (19). Partially purified ACC
protein from livers of mice was incubated with recombinant
mouse MIG12, 14C-labeled bicarbonate, and ATP, and the incor-
poration of 14C into malonyl-CoA was quantified as a measure of
ACC activity (Fig. 3A). In the presence of 1 mM citrate, MIG12
increased ACC activity by 58-fold in a concentration-dependent
manner (Fig. 3A). In the absence of MIG12, the concentration of
citrate required for half-maximal ACC activity was ∼1.6 mM. In
the presence of MIG12 the citrate activation curve was shifted
markedly to the left, with the half-maximal activation at
0.2 mM (Fig. 3B).
The use of partially purified hepatic ACC in these activity
assays could not reveal whether MIG12 enhanced the activity
of ACC1, ACC2, or both enzymes. Therefore, ACC activity assays
were repeated using recombinant ACC1 and ACC2 proteins (24).
As shown in Fig. 4A, the addition of MIG12 to ACC1 or ACC2
increased the activity of each enzyme by ∼10-fold and ∼4-fold,
respectively, at the highest MIG12 concentrations tested.
MIG12 had a greater ability to enhance ACC1 activity at lower
concentrations compared to ACC2. The ability of MIG12 to in-
crease ACC1 and ACC2 activity as a function of citrate concen-
tration was also determined (Fig. 4B). MIG12 increased ACC1
activity by more than sixfold even in the complete absence of
citrate, whereas MIG12’s ability to increase ACC2 activity
required the presence of citrate in the reaction (Fig. 4B).
MIG12 Does Not Alter ACC Phosphorylation.ACC activity is reduced
by phosphorylation and increased by dephosphorylation (4). To
determine whether MIG12 increased ACC activity by altering
the phosphorylated state of ACC, avidin-mediated highly purified
mouse ACC was incubated with BSA or MIG12 for 30 min,
and the proteins were subjected to SDS/PAGE and immunoblot
analysis using streptavidin that detects total ACC or an antibody
that only detects phosphorylated ACC (Fig. S5A). The ratio of
phosphorylated ACC to total ACC was not significantly changed
in the presence and absence of recombinant MIG12. To confirm
that phosphorylation was not changed by MIG12 in vivo, mice
were injected with a MIG12 or control adenovirus and livers were
harvested. The ratio of phosphorylated ACC to total ACC was
unchanged despite a significant increase in ACC activity
(Fig. S5B–D). Combined, these results suggest that MIG12 does
not alter the phosphorylated state of ACC.
Fig. 3. Total ACC activity is increased by MIG12. ACC was partially purified
from livers of mice and MIG12 was produced as described in Methods.
(A) Partially purified ACC (55 μg) was preincubated with the indicated
amounts of MIG12 or BSA, and 1.0 mM citrate for 30 min and ACC activity
assays were performed as described inMethods. Each value is the mean S:E:
of three independent reactions. Similar results were obtained in three inde-
pendent studies. (B) Partially purified ACC (55 μg) was preincubated with
20 μg of recombinant MIG12 or BSA and ACC activity was measured in
the presence of increasing concentrations of citrate as described inMethods.
Each value is the mean S:E: of three independent reactions. Similar results
were obtained in three independent studies.
Fig. 4. RecombinantACC1 andACC2 activity is induced byMIG12. (A) Recom-
binant human ACC1 (0.5 μg) and ACC2 (0.5 μg) were incubated with the indi-
cated amounts of mouse MIG12 or BSA and the ACC activity was measured as
described inMethods. TheACC1reactions contained0mMcitrateand theACC2
reactions contained 1 mM citrate. Each value is the mean standard error of
three independent reactions. Similar resultswere obtained in two independent
studies. (B) Recombinant ACC1 (0.5 μg) and ACC2 (0.5 μg) were incubated with
2 μg of MIG12 or BSA in the presence of the indicated concentration of citrate
andACCactivitywasmeasured. Each value is themean S:E: of three indepen-
dent reactions. Similar results were obtained in two independent studies.
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MIG12 Induces ACC Polymerization. Activation of ACC by citrate is
associated with the formation of ACC polymers (19). To deter-
mine whether MIG12 influences ACC polymerization, MIG12
was added to recombinant ACC1 and ACC2 in the presence
or absence of citrate and the proteins subjected to nondenaturing
blue-native gel electrophoresis. ACC1 and ACC2 in their least
active states exist as dimers (4). The addition of increasing con-
centrations of MIG12 to ACC1 induced the formation of very
high molecular weight polymers in a concentration-dependent
manner even in the absence of citrate (Fig. 5A). A similar series
of studies were performed using recombinant ACC2 in the pre-
sence of 0.625 mM citrate, because MIG12 had no or little effect
on ACC2 activity in the absence of citrate. While MIG12 also in-
duced the polymerization of ACC2, the concentration of MIG12
required was higher than that required for ACC1 polymerization
(Fig. 5B). Addition of citrate alone to ACC1 or ACC2 resulted in
a shift to higher order oligomers that are approximately the pre-
dicted size of an ACC tetramer (Fig. 5C and D). The addition of
MIG12 to ACC1 induced the formation of the high molecular
weight ACC1 form even in the absence of citrate (Fig. 5C), while
the proportion of high molecular weight ACC2 increased with in-
creasing citrate concentrations (Fig. 5D).
To confirm that the increase in ACC molecular weight induced
by MIG12 was actually a result of polymerization, the mixture of
ACC and MIG12 was subjected to negative staining electron
microscopy. As shown in Fig. S6, MIG12 induced the formation
of long filamentous ACC1 and ACC2 polymers.
MIG12 Is Incorporated into the ACC Polymer. To determine whether
the MIG12 catalytically induced ACC polymerization or whether
MIG12 was directly incorporated into the ACC polymer, MIG12
was incubated with ACC1 or ACC2 in the presence or absence of
citrate and the mixture was subjected to FPLC. ACC and MIG12
proteins were detected by immunoblot analysis in each fraction.
As shown in Fig. 6A, mixing MIG12 and ACC1 shifted the
fractions in which ACC1 was detected to those corresponding
to higher molecular weight proteins, consistent with the findings
in Fig. 5. In preliminary experiments, we found that MIG12 exists
predominantly as a dimer as determined by analytical ultracen-
trifugation, but in gel filtration studies higher order tetramers
were also observed. Using the Superose 6 column, MIG12 was
consistently detected only in fractions 14–18. In the presence
of ACC1, MIG12 was detected in all fractions that also contained
ACC1 (Fig. 6A). In the presence of 5 mM citrate, all MIG12 was
detected exclusively in high molecular weight fractions 7–10 that
contained ACC1 (Fig. 6B).
The shift in size induced in ACC2 byMIG12 was more subtle in
the absence of citrate (Fig. 6C). This result is consistent with data
of Fig. 5 that demonstrated minimal polymerization of ACC2 in
the absence of citrate; however, in the presence of 5 mM citrate,
ACC2 shifted to the highermolecular weight fractions andMIG12
was also incorporated into this complex (Fig. 6D). Combined,
these results suggested that MIG12 is bound to ACC and that
the protein becomes an integral component of the high molecular
weight ACC polymer.
MIG12 Induces Polymerization of ACC in Living Animals. To confirm
that MIG12 was also capable of inducing ACC polymerization in
vivo, mice were injected with an adenovirus expressing β-gal or
MIG12, liver was harvested, and cytosolic proteins were sub-
jected to blue-native gel electrophoresis and immunoblot analysis
for ACC. Overexpression of MIG12 in mouse liver induced the
formation of high molecular weight ACC in a manner similar to
that observed with purified recombinant proteins (Fig. 7).
Discussion
In the current report, we demonstrate that MIG12 is responsible
for the tertiary regulation of ACC by its ability to bind and induce
polymerization, which in turn increases the enzymatic activity of
ACC. Adenoviral overexpression of MIG12 in mice also induced
the formation of ACC polymers, which was associated with in-
creased rates of de novo FA synthesis in liver leading to hepatic
steatosis.
Previously, polymerization of ACC had been shown to be
induced by high concentrations of citrate (19). This observation
is consistent with the physiologic changes that are associated with
states of increased lipogenesis in liver that arise when excess
glucose is converted to citrate in the mitochondria and then trans-
ported to the cytosol for utilization by ACL to produce acetyl-
CoA, the substrate of ACC. While we could demonstrate that
Fig. 5. Induction of ACC1 and ACC2 polymerization
by MIG12. (A) Recombinant ACC1 (6 μg) was incu-
bated with 0, 0.23, 0.45, 0.9, 1.8, and 3.6 μg of
MIG12 or BSA in presence of 0 mM citrate. (B) Recom-
binant ACC2 (6 μg) was incubated with 0, 0.23, 0.45,
0.9, 1.8, and 3.6 μg of MIG12 or BSA in presence
0.625 mM citrate. (C) Recombinant ACC1 (6 μg) was
incubatedwith 0.9 μg ofMIG12 or BSA in the presence
of 0, 0.3, 0.6, 1.25, 2.5, and 5 mM citrate. (D) Recom-
binant ACC2 (6 μg) was incubated with 0.9 μg of
MIG12 or BSA in the presence of 0, 0.3, 0.6, 1.25,
2.5, and 5 mM citrate. The incubated proteins were
subjected to blue-native gel electrophoresis (3.5–
10% gradient gels) and the proteins were transferred
to nitrocellulose membrane. Immunoblots were
performed using a polyclonal anti-MYC antibody to
detect ACC1 and ACC2.
Kim et al. PNAS ∣ May 25, 2010 ∣ vol. 107 ∣ no. 21 ∣ 9629
BI
O
CH
EM
IS
TR
Y
citrate alone could induce higher order oligomers of recombinant
ACC1 and ACC2 that were approximately the size of a tetramer,
the formation of the high molecular weight polymers required the
presence of MIG12 as assessed by blue-native gel electrophoresis
(Fig. 5). Furthermore, the concentration of citrate required
for half-maximal ACC activity was greater than 1.5 mM, which
is higher than the normal cellular concentration of citrate
(∼0.6–1.25 mM) (18). MIG12 significantly shifted the citrate ac-
tivation curve to the left, lowering the concentration of citrate
required for half-maximal activity to ∼0.2 mM, which is well with-
in the physiological range. In the case of ACC1, MIG12 induced
polymerization and increased enzyme activity even in the absence
of citrate, while ACC2 required a minimal citrate concentration.
The mechanism responsible for the difference in citrate require-
ments for MIG12-induced ACC1 and ACC2 polymerization was
not determined in this study; however, the relative resistance of
ACC2 to polymerize has been reported recently (25).
The ability of MIG12 to induce ACC polymerization raised the
question of whetherMIG12 functioned as a catalyst for ACCpoly-
merization or whether MIG12 actually integrated into the ACC
polymer. The experiments of Fig. 6 suggested that MIG12 was di-
rectly incorporated into the ACC polymer. To our knowledge, this
is a previously undescribed example of a protein that regulates the
activity of a metabolic enzyme by binding and inducing a higher
order structure, which in turn increases enzymatic activity. Esti-
mates of the stoichiometry ofMIG12 and ACC from the gel filtra-
tion fractions shown in Fig. 6 suggest that the MIG12-ACC1 ratio
is∼1∶1 in the absence of citrate. Similar estimates for ACC2 in the
presence of citrate suggest a slightly higher MIG12:ACC2 ratio of
∼2∶1. The exact stoichiometry of MIG12 to ACC will ultimately
require crystallographic analysis of the MIG12:ACC complex.
The MIG12 protein in mouse liver runs as a doublet of
∼22 kDa and 24 kDa on SDS/PAGE. The doublet appears to
be due to differences in phosphorylation because the treatment
of recombinant MIG12 with alkaline phosphatase to completely
dephosphorylate the protein resulted in a single MIG12 band by
immunoblot analysis. To confirm that MIG12 was phosphory-
lated, the ∼22 kDa and ∼24 kDa recombinant MIG12 protein
produced in CHO cells was subjected to digestion by trypsin
and endoproteinase AspN, and phosphorylation sites were iden-
tified by LC/MS/MS. The ∼22 kDa MIG12 contained five phos-
phorylated serine residues (S44, S71, S74, S110, and S134),
whereas the ∼24 kDa MIG12 contained three additional phos-
phorylated residues (T66, T67, and S78). In the mouse fasting/re-
feeding studies, both bands appear to be regulated in parallel.
Whether alternatively phosphorylated forms of MIG12 have dif-
ferent activities is currently not known; however, in preliminary
experiments recombinant MIG12 purified from Escherichia coli
that produces MIG12 with no posttranslational modifications
behaves the same as MIG12 produced in CHO cells, which pro-
duces both forms of phosphorylated MIG12.
A search of the National Institutes of Health database for
proteins related to MIG12 only reveals one protein, designated
SPOT 14 (S14), which has 36% amino acid identity with MIG12
(21). S14 is also regulated by SREBPs in a manner similar to
MIG12 (20) and knockout mice have reduced fatty acid synthesis
in mammary glands (26). Recombinant S14 was also tested in vi-
tro and no change in ACC1 or ACC2 activity was found (Fig. S7).
Thus, despite the similar regulation and sequence homology, only
MIG12 is capable of inducing ACC activity.
MIG12 mRNA and protein levels are regulated in parallel with
SREBP-1c and all other enzymes in the FA biosynthetic pathway.
Our previous microarray studies demonstrated that the mRNA
for MIG12 was markedly induced in livers of SREBP-1 transgenic
mice and significantly reduced in mice that lack SREBPs (20).
While we did not formally demonstrate that SREBP-1 binds to
the promoter of MIG12, a classic sterol response element does
exist in the 5′-flanking region of the mouseMig12 gene ∼174 base
pairs 5′ to the transcriptional start site. Previously, most genes
identified as direct transcriptional targets of SREBP-1 have been
enzymes that carry out the synthesis of FAs and TGs (20). The
identification of MIG12 as a protein that activates ACC enzy-
matic activity by inducing the polymerization of the protein adds
Fig. 6. MIG12 incorporates into ACC polymers. (A) Recombinant ACC1
(80 μg) was incubated with 10 μg of MIG12 or BSA in 0 mM citrate for
5 min at RT. (B) Recombinant ACC1 (80 μg) was incubated with 10 μg of
MIG12 or BSA in 5 mM citrate for 5 min at RT. (C) Recombinant ACC2
(80 μg) was incubated with 10 μg of MIG12 or BSA in 0 mM citrate for
5 min at RT. (D) Recombinant ACC2 (80 μg) was incubated with 10 μg of
MIG12 or BSA in 5 mM citrate for 5 min at RT. The mixtures were subjected
to FPLC using a Superose 6 size exclusion column and 10 μl from the each
fraction was subjected to 5.5% SDS/PAGE for ACC1 and ACC2 immunoblots
or 12% SDS/PAGE for MIG12 immunoblots. Proteins were transferred to
nitrocellulose membrane and ACC1 and ACC2 proteins were detected using
an anti-MYC antibody andMIG12 was detected using a polyclonal antimouse
MIG12 antibody.
Fig. 7. MIG12-induced ACC polymerization in living animals. Five male mice
were injected with an adenovirus expressing either β-gal or MIG12
(1011 particles∕mouse). Mice were killed 5 days after the injection and liver
was harvested. Pooled liver cytosolic proteins (50 μg) from each group of mice
were subjected to 3.5–10% gradient blue-native gel electrophoresis and
ACC1 protein was detected by immunoblot analysis.
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a new posttranscriptional layer of regulation of FA synthesis by
SREBP-1c. The overall importance of this tertiary level of ACC
regulation in the control of FA synthesis rates in liver will ulti-
mately require the generation and characterization of MIG12
knockout mice.
Methods
Generation of Polyclonal Antimouse MIG12 Antibody. Recombinant mouse
ðHisÞ6-MIG12 expressed in the E. coliwas purified with Ni-NTA affinity column
using QIAexpressionist system (Qiagen) according to the manufacturer’s
protocol and is described in detail in SI Supplemental Methods. Recombinant
MIG12 was injected into rabbits to generate polyclonal antibody as
described (27).
Production and Expression of MIG12 Adenovirus in Mice. Mouse MIG12 cDNA
was subcloned into pShuttle-CMV transfer vector and adenovirus produced
per protocol. Virus (1011 particles∕mouse) was injected to C57BL/6 mice via
tail vein and tissues harvested at the indicated times. Animal experiments
were approved by the Institutional Animal Care and Research Advisory
Committee at the University of Texas Southwestern.
MIG12 Immunoprecipitation from Mouse Liver and Immunoblot Analysis. Five
male C57BL/6 mice were injected with an adenovirus (1011 particles∕mouse)
expressing either β-gal or MIG12-FLAG. Two days after injection, mice were
fasted for 12 h (F) or refed a high carbohydrate diet (MP Biomedicals, Cat #
960238) for 12 h following a 12 h fast (R). In separate experiments to precipi-
tate endogenous MIG12, 5 male mice were subjected to the same feeding
paradigm. Livers were harvested and proteins were immunoprecipitated
and identified by immunoblot analysis as described in SI Supplemental
Methods.
FA and Cholesterol Synthesis. C57BL/6 mice were injected with adenovirus
that expressed MIG12 or β-gal (1011 particles∕mouse). Five days after virus
administration, mice were injected intraperitoneally with 3H-labeled water
(50 mCi) and rates of hepatic FA and cholesterol synthesis were determined
as described (28).
Partial Purification of ACC from Mouse Liver. ACC was enriched from mouse
liver using methods of Thampy et. al. (29) with slight modifications described
in Supplemental Methods.
In Vitro ACC Activity Assay. ACC activity was measured as described (19, 30)
with minor modifications as described in SI Supplemental Methods.
Analysis of ACC Polymerization by Blue-Native Gels. Recombinant ACC1 or
ACC2 (6 μg) was incubated at 37 °C for 10 min with various concentrations
of recombinant mouse MIG12 or BSA in buffer C, which contained 40 mM
HEPES, pH 7.6, and 1 mM DTT (final volume, 75 μl). In separate experiments,
recombinant ACC1 or ACC2 (6 μg) was incubated with recombinant MIG12 or
BSA (0.9 μg) in the presence of various citrate concentrations in buffer C at 37
°C for 10 min (final volume, 75 μl). After the 10 min incubation, the mixture
was subjected to 3.5–10% blue-native gel electrophoresis for 12 h at 4 °C and
immunoblot analysis performed as described in SI Supplemental Methods.
Analysis of ACC Polymerization by FPLC. Human recombinant ACC1 or ACC2
(80 μg) was incubated with MIG12 or BSA (10 μg), and the mixture was
applied to FPLC using a Superose 6 size exclusion column at a flow rate of
0.4 ml∕min. The first 7 ml of the flow through was discarded and every
subsequent 1 ml fraction was collected. An aliquot (10 μl) from each fraction
was subjected to SDS/PAGE and the proteins were transferred to a nitrocel-
lulose membrane for immunoblot analysis as described in SI Supplemental
Methods.
Analysis of ACC Polymerization in Mouse Liver. Five male mice were injected
with an adenovirus expressing either β-gal or MIG12 (1011 particles∕mouse).
Mice were killed 5 d after the adenoviral injection and livers were harvested.
Equal aliquots of liver (200 mg) from each mouse were pooled (1 g) and
homogenized in 10 ml of a buffer containing 40 mM HEPES, pH 7.6,
0.25 M sucrose, and protease inhibitors (Roche). Cytosolic proteins (50 μg)
were subjected to 3.5–10% gradient blue-native gel electrophoresis for
ACC1 immunoblot analysis as described above.
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